Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;60(11):1766-71.
doi: 10.1002/pbc.24667. Epub 2013 Jul 2.

Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy

Affiliations

Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy

Sogol Mostoufi-Moab et al. Pediatr Blood Cancer. 2013 Nov.

Abstract

Background: Childhood cancer survivors treated with cranial or total body irradiation (TBI) are at risk for growth hormone deficiency (GHD). Recombinant growth hormone (rhGH) therapy is associated with slipped capital femoral epiphysis (SCFE). We compared the incidence of SCFE after TBI versus cranial irradiation (CI) in childhood cancer survivors treated with rhGH.

Procedure: Retrospective cohort study (1980-2010) of 119 survivors treated with rhGH for irradiation-induced GHD (56 TBI; 63 CI). SCFE incidence rates were compared in CI and TBI recipients, and compared with national registry SCFE rates in children treated with rhGH for idiopathic GHD.

Results: Median survivor follow-up since rhGH initiation was 4.8 (range 0.2-18.3) years. SCFE was diagnosed in 10 subjects post-TBI and none after CI (P < 0.001). All 10 subjects had atypical valgus SCFE, and 7 were bilateral at presentation. Within TBI recipients, age at cancer diagnosis, sex, race, underlying malignancy, age at radiation, and age at initiation of rhGH did not differ significantly between those with versus without SCFE. The mean (SD) age at SCFE diagnosis was 12.3 (2.7) years and median duration of rhGH therapy to SCFE was 1.8 years. The SCFE incidence rate after TBI exposure was 35.9 per 1,000 person years, representing a 211-fold greater rate than reported in children treated with rhGH for idiopathic GH deficiency.

Conclusions: The markedly greater SCFE incidence rate in childhood cancer survivors with TBI-associated GHD, compared with rates in children with idiopathic GHD, suggests that cancer treatment effects to the proximal femoral physis may contribute to SCFE.

Keywords: SCFE; childhood cancer survivors; cranial irradiation; growth hormone; total body irradiation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Nothing to declare.

Figures

Fig. 1
Fig. 1
Antero-posterior (AP) (A) and frog-leg lateral radiographs (B) showing left lateral and posterior (valgus) slip of the capital femoral epiphysis in a patient on rhGH therapy after total body irradiation (TBI). C: Pre-operative AP radiograph of the pelvis showing bilateral valgus slipped capital femoral epiphysis (SCFE) in a childhood cancer survivor on rhGH after TBI. D: Post-operative AP radiograph of the same patient demonstrating screw fixation of the bilateral SCFE.

Comment in

Similar articles

Cited by

References

    1. Loder RT. Slipped capital femoral epiphysis. Am Fam Physician. 1998;57:2135–2142. 2148–2150. - PubMed
    1. Gholve PA, Cameron DB, Millis MB. Slipped capital femoral epiphysis update. Curr Opin Pediatr. 2009;21:39–45. - PubMed
    1. Peck D. Slipped capital femoral epiphysis: Diagnosis and management. Am Fam Physician. 2010;82:258–262. - PubMed
    1. Lehmann CL, Arons RR, Loder RT, et al. The epidemiology of slipped capital femoral epiphysis: An update. J Pediatr Orthop. 2006;26:286–290. - PubMed
    1. Papavasiliou KA, Kirkos JM, Kapetanos GA, et al. Potential influence of hormones in the development of slipped capital femoral epiphysis: A preliminary study. J Pediatr Orthop B. 2007;16:1–5. - PubMed

Publication types

Substances

LinkOut - more resources